Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of remazolam on emergence agitation in patients undergoing nasal surgery
ChiCTR2400085806Phase 4Not yet recruiting
- Sponsor
- Nanchong City Central Hospital
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam mesylate in Emergence agitation (EA) (2 arms), sponsored by Nanchong City Central Hospital. Primary endpoint: Emergence agitation. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
remimazolam mesylate
03
Conditions
Emergence agitation (EA)
Beyond the preview
Go deeper on ChiCTR2400085806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085806.